The Effects of Barley-Derived Soluble Fiber on Serum Lipids
Abstract Purpose We wanted to determine the association between consumption of barley and changes in plasma lipids in healthy and hypercholesterolemic men and women. Methods A systematic literature search was conducted from the earliest possible date through January 2008. Trials were included in the...
Gespeichert in:
Veröffentlicht in: | Annals of family medicine 2009-03, Vol.7 (2), p.157-163 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 163 |
---|---|
container_issue | 2 |
container_start_page | 157 |
container_title | Annals of family medicine |
container_volume | 7 |
creator | Talati, Ripple, PharmD Baker, William L., PharmD, BCPS Pabilonia, Mary S., PharmD White, C. Michael, PharmD, FCP, FCCP Coleman, Craig I., PharmD |
description | Abstract Purpose We wanted to determine the association between consumption of barley and changes in plasma lipids in healthy and hypercholesterolemic men and women. Methods A systematic literature search was conducted from the earliest possible date through January 2008. Trials were included in the analysis if they were randomized controlled trials of barley that reported efficacy data on at least 1 lipid endpoint. A DerSimonian and Laird random-effects model was used in calculating the weighted mean difference (WMD) and its 95% confidence interval (CI). Statistical heterogeneity was addressed using the I statistic. Visual inspection of funnel plots, Egger's weighted regression statistics, and the trim and fill method were used to assess for publication bias. Results We found 8 trials (n = 391 patients) of 4 to 12 weeks' duration evaluating the lipid-reducing effects of barley. The use of barley significantly lowered total cholesterol (weighted mean difference [WMD], −13.38 mg/dL; 95% CI, −18.46 to −8.31 mg/dL), low-density lipoprotein (LDL) cholesterol (WMD, −10.02 mg/dL; 95% CI, −14.03 to −6.00 mg/dL) and triglycerides (WMD, −11.83 mg/dL; 95% CI, −20.12 to −3.55 mg/dL) but did not appear to significantly alter high-density lipoprotein (HDL) cholesterol ( P = .07). Conclusion Barley-derived β-glucan appears to beneficially affect total cholesterol, LDL-cholesterol, and triglycerides, but not HDL-cholesterol. |
doi_str_mv | 10.1370/afm.917 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2653960</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1544170909600330</els_id><sourcerecordid>67013143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-3634931048a1f16b4414b2ee2c4d798841e37ce18dd44d934d18cf20d16615cf3</originalsourceid><addsrcrecordid>eNpVkU9rGzEQxUVISFK39BuUPaWnTTWSvNqlEEhcOw0YenB6Flpp1MjVrlzJa_C375qY_DnNwDzePH6PkM9Ar4FL-k277roBeUIuYSpECRLk6ctOmwvyIec1pQwYZ-fkAhomeS3hknx_fMJi7hyabS6iK-50Crgvf2DyO7TFKoahDVgsfIupiH2xwjR0xdJvvM0fyZnTIeOn45yQ34v54-xnufx1_zC7XZZmCnJb8oqLhgMVtQYHVSsEiJYhMiOsbOpaAHJpEGprhbANFxZq4xi1UFUwNY5PyM2z72ZoO7QG-23SQW2S73Taq6i9en_p_ZP6E3eKVVPeVHQ0uDoapPhvwLxVnc8GQ9A9xiGrSlLgIPgo_PosNCnmnNC9PAGqDqDVCFqNoEfll7eZXnVHsq-hcSSz85iUCb73Roe_uMe8jkPqR2gKVGaKqtWhq0NVdAxMOaf8P1oXjFw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67013143</pqid></control><display><type>article</type><title>The Effects of Barley-Derived Soluble Fiber on Serum Lipids</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Talati, Ripple, PharmD ; Baker, William L., PharmD, BCPS ; Pabilonia, Mary S., PharmD ; White, C. Michael, PharmD, FCP, FCCP ; Coleman, Craig I., PharmD</creator><creatorcontrib>Talati, Ripple, PharmD ; Baker, William L., PharmD, BCPS ; Pabilonia, Mary S., PharmD ; White, C. Michael, PharmD, FCP, FCCP ; Coleman, Craig I., PharmD</creatorcontrib><description>Abstract Purpose We wanted to determine the association between consumption of barley and changes in plasma lipids in healthy and hypercholesterolemic men and women. Methods A systematic literature search was conducted from the earliest possible date through January 2008. Trials were included in the analysis if they were randomized controlled trials of barley that reported efficacy data on at least 1 lipid endpoint. A DerSimonian and Laird random-effects model was used in calculating the weighted mean difference (WMD) and its 95% confidence interval (CI). Statistical heterogeneity was addressed using the I statistic. Visual inspection of funnel plots, Egger's weighted regression statistics, and the trim and fill method were used to assess for publication bias. Results We found 8 trials (n = 391 patients) of 4 to 12 weeks' duration evaluating the lipid-reducing effects of barley. The use of barley significantly lowered total cholesterol (weighted mean difference [WMD], −13.38 mg/dL; 95% CI, −18.46 to −8.31 mg/dL), low-density lipoprotein (LDL) cholesterol (WMD, −10.02 mg/dL; 95% CI, −14.03 to −6.00 mg/dL) and triglycerides (WMD, −11.83 mg/dL; 95% CI, −20.12 to −3.55 mg/dL) but did not appear to significantly alter high-density lipoprotein (HDL) cholesterol ( P = .07). Conclusion Barley-derived β-glucan appears to beneficially affect total cholesterol, LDL-cholesterol, and triglycerides, but not HDL-cholesterol.</description><identifier>ISSN: 1544-1709</identifier><identifier>EISSN: 1544-1717</identifier><identifier>DOI: 10.1370/afm.917</identifier><identifier>PMID: 19273871</identifier><language>eng</language><publisher>United States: American Academy of Family Physicians</publisher><subject>Cholesterol - blood ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Dietary Fiber - administration & dosage ; Female ; Hordeum - chemistry ; Humans ; Hypercholesterolemia - blood ; Hypercholesterolemia - drug therapy ; Internal Medicine ; Lipids - blood ; Male ; Phytotherapy ; Randomized Controlled Trials as Topic ; Systematic Reviews ; Triglycerides - blood</subject><ispartof>Annals of family medicine, 2009-03, Vol.7 (2), p.157-163</ispartof><rights>Annals of Family Medicine, Inc.</rights><rights>Copyright © Copyright 2009 Annals of Family Medicine, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-3634931048a1f16b4414b2ee2c4d798841e37ce18dd44d934d18cf20d16615cf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653960/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653960/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19273871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Talati, Ripple, PharmD</creatorcontrib><creatorcontrib>Baker, William L., PharmD, BCPS</creatorcontrib><creatorcontrib>Pabilonia, Mary S., PharmD</creatorcontrib><creatorcontrib>White, C. Michael, PharmD, FCP, FCCP</creatorcontrib><creatorcontrib>Coleman, Craig I., PharmD</creatorcontrib><title>The Effects of Barley-Derived Soluble Fiber on Serum Lipids</title><title>Annals of family medicine</title><addtitle>Ann Fam Med</addtitle><description>Abstract Purpose We wanted to determine the association between consumption of barley and changes in plasma lipids in healthy and hypercholesterolemic men and women. Methods A systematic literature search was conducted from the earliest possible date through January 2008. Trials were included in the analysis if they were randomized controlled trials of barley that reported efficacy data on at least 1 lipid endpoint. A DerSimonian and Laird random-effects model was used in calculating the weighted mean difference (WMD) and its 95% confidence interval (CI). Statistical heterogeneity was addressed using the I statistic. Visual inspection of funnel plots, Egger's weighted regression statistics, and the trim and fill method were used to assess for publication bias. Results We found 8 trials (n = 391 patients) of 4 to 12 weeks' duration evaluating the lipid-reducing effects of barley. The use of barley significantly lowered total cholesterol (weighted mean difference [WMD], −13.38 mg/dL; 95% CI, −18.46 to −8.31 mg/dL), low-density lipoprotein (LDL) cholesterol (WMD, −10.02 mg/dL; 95% CI, −14.03 to −6.00 mg/dL) and triglycerides (WMD, −11.83 mg/dL; 95% CI, −20.12 to −3.55 mg/dL) but did not appear to significantly alter high-density lipoprotein (HDL) cholesterol ( P = .07). Conclusion Barley-derived β-glucan appears to beneficially affect total cholesterol, LDL-cholesterol, and triglycerides, but not HDL-cholesterol.</description><subject>Cholesterol - blood</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Dietary Fiber - administration & dosage</subject><subject>Female</subject><subject>Hordeum - chemistry</subject><subject>Humans</subject><subject>Hypercholesterolemia - blood</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Internal Medicine</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Phytotherapy</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Systematic Reviews</subject><subject>Triglycerides - blood</subject><issn>1544-1709</issn><issn>1544-1717</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU9rGzEQxUVISFK39BuUPaWnTTWSvNqlEEhcOw0YenB6Flpp1MjVrlzJa_C375qY_DnNwDzePH6PkM9Ar4FL-k277roBeUIuYSpECRLk6ctOmwvyIec1pQwYZ-fkAhomeS3hknx_fMJi7hyabS6iK-50Crgvf2DyO7TFKoahDVgsfIupiH2xwjR0xdJvvM0fyZnTIeOn45yQ34v54-xnufx1_zC7XZZmCnJb8oqLhgMVtQYHVSsEiJYhMiOsbOpaAHJpEGprhbANFxZq4xi1UFUwNY5PyM2z72ZoO7QG-23SQW2S73Taq6i9en_p_ZP6E3eKVVPeVHQ0uDoapPhvwLxVnc8GQ9A9xiGrSlLgIPgo_PosNCnmnNC9PAGqDqDVCFqNoEfll7eZXnVHsq-hcSSz85iUCb73Roe_uMe8jkPqR2gKVGaKqtWhq0NVdAxMOaf8P1oXjFw</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Talati, Ripple, PharmD</creator><creator>Baker, William L., PharmD, BCPS</creator><creator>Pabilonia, Mary S., PharmD</creator><creator>White, C. Michael, PharmD, FCP, FCCP</creator><creator>Coleman, Craig I., PharmD</creator><general>American Academy of Family Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090301</creationdate><title>The Effects of Barley-Derived Soluble Fiber on Serum Lipids</title><author>Talati, Ripple, PharmD ; Baker, William L., PharmD, BCPS ; Pabilonia, Mary S., PharmD ; White, C. Michael, PharmD, FCP, FCCP ; Coleman, Craig I., PharmD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-3634931048a1f16b4414b2ee2c4d798841e37ce18dd44d934d18cf20d16615cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Cholesterol - blood</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Dietary Fiber - administration & dosage</topic><topic>Female</topic><topic>Hordeum - chemistry</topic><topic>Humans</topic><topic>Hypercholesterolemia - blood</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Internal Medicine</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Phytotherapy</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Systematic Reviews</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Talati, Ripple, PharmD</creatorcontrib><creatorcontrib>Baker, William L., PharmD, BCPS</creatorcontrib><creatorcontrib>Pabilonia, Mary S., PharmD</creatorcontrib><creatorcontrib>White, C. Michael, PharmD, FCP, FCCP</creatorcontrib><creatorcontrib>Coleman, Craig I., PharmD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of family medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Talati, Ripple, PharmD</au><au>Baker, William L., PharmD, BCPS</au><au>Pabilonia, Mary S., PharmD</au><au>White, C. Michael, PharmD, FCP, FCCP</au><au>Coleman, Craig I., PharmD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effects of Barley-Derived Soluble Fiber on Serum Lipids</atitle><jtitle>Annals of family medicine</jtitle><addtitle>Ann Fam Med</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>7</volume><issue>2</issue><spage>157</spage><epage>163</epage><pages>157-163</pages><issn>1544-1709</issn><eissn>1544-1717</eissn><abstract>Abstract Purpose We wanted to determine the association between consumption of barley and changes in plasma lipids in healthy and hypercholesterolemic men and women. Methods A systematic literature search was conducted from the earliest possible date through January 2008. Trials were included in the analysis if they were randomized controlled trials of barley that reported efficacy data on at least 1 lipid endpoint. A DerSimonian and Laird random-effects model was used in calculating the weighted mean difference (WMD) and its 95% confidence interval (CI). Statistical heterogeneity was addressed using the I statistic. Visual inspection of funnel plots, Egger's weighted regression statistics, and the trim and fill method were used to assess for publication bias. Results We found 8 trials (n = 391 patients) of 4 to 12 weeks' duration evaluating the lipid-reducing effects of barley. The use of barley significantly lowered total cholesterol (weighted mean difference [WMD], −13.38 mg/dL; 95% CI, −18.46 to −8.31 mg/dL), low-density lipoprotein (LDL) cholesterol (WMD, −10.02 mg/dL; 95% CI, −14.03 to −6.00 mg/dL) and triglycerides (WMD, −11.83 mg/dL; 95% CI, −20.12 to −3.55 mg/dL) but did not appear to significantly alter high-density lipoprotein (HDL) cholesterol ( P = .07). Conclusion Barley-derived β-glucan appears to beneficially affect total cholesterol, LDL-cholesterol, and triglycerides, but not HDL-cholesterol.</abstract><cop>United States</cop><pub>American Academy of Family Physicians</pub><pmid>19273871</pmid><doi>10.1370/afm.917</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1544-1709 |
ispartof | Annals of family medicine, 2009-03, Vol.7 (2), p.157-163 |
issn | 1544-1709 1544-1717 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2653960 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Cholesterol - blood Cholesterol, HDL - blood Cholesterol, LDL - blood Dietary Fiber - administration & dosage Female Hordeum - chemistry Humans Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Internal Medicine Lipids - blood Male Phytotherapy Randomized Controlled Trials as Topic Systematic Reviews Triglycerides - blood |
title | The Effects of Barley-Derived Soluble Fiber on Serum Lipids |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T06%3A17%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effects%20of%20Barley-Derived%20Soluble%20Fiber%20on%20Serum%20Lipids&rft.jtitle=Annals%20of%20family%20medicine&rft.au=Talati,%20Ripple,%20PharmD&rft.date=2009-03-01&rft.volume=7&rft.issue=2&rft.spage=157&rft.epage=163&rft.pages=157-163&rft.issn=1544-1709&rft.eissn=1544-1717&rft_id=info:doi/10.1370/afm.917&rft_dat=%3Cproquest_pubme%3E67013143%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67013143&rft_id=info:pmid/19273871&rft_els_id=1_s2_0_S1544170909600330&rfr_iscdi=true |